Ömer Çağrı Akçin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ömer Çağrı Akçin has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Ceren Damla Durmaz
Department of Medical Genetics, School of Medicine, Hacettepe University, Ankara, Turkey
2 shared publications - Dilsu Dicle Erkan
Department of Medical Genetics, Ankara Etlik City Hospital 1 Turkey
2 shared publications - Naz Güleray Lafcı
Department of Medical Genetics, Faculty of Medicine, Hacettepe University, Ankara, Turkey
2 shared publications Deniz Ateş Özdemir
Department of Medical Pathology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
1 shared publicationFatih Kuş
Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
1 shared publicationJürgen Neesen
Institute of Medical Genetics, Centre for Pathobiochemistry and Genetics, Medical University of Vienna, Vienna, Austria
1 shared publication
Latest Publications
- Open Access
- 18 February 2026
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (3) , 429-437
TMC6/8-associated epidermodysplasia verruciformis: germline variants and a complex structural alteration in a skin cancer predisposition syndrome
Hereditary epidermodysplasia verruciformis (EV) represents a paradigmatic inherited cutaneous syndrome linking viral susceptibility, immunity, and oncogenesis. Although biallelic variants in CIB1 , TMC6 , and TMC8 —encoding components of the keratinocyte-intrinsic antiviral complex—underlie most cases, the full mutational spectrum and its oncologic implications remain incompletely defined. We performed integrated genomic, histopathological, and longitudinal clinical analyses in six affected individuals from five unrelated families with confirmed hereditary EV. Comprehensive short-read sequencing, copy-number assessment, and optical genome mapping (OGM) were used to delineate the underlying genetic alterations, followed by long-range PCR and Sanger validation. Pathogenic or likely pathogenic germline variants affecting TMC6 or TMC8 were identified in all probands, providing molecular confirmation of disease. Four variants were novel, including splice-site, frameshift, and in-frame deletions. In one proband, OGM revealed a previously unrecognised complex del–inv–del structural variant spanning both TMC6 and TMC8 —the first reported example in hereditary EV. This rearrangement, confirmed at base-pair resolution, co-segregated with a synonymous TMC8 variant that served as a practical haplotypic marker for carrier testing. Clinically, all patients developed cutaneous squamous cell carcinoma (SCC), and several exhibited multifocal or aggressive disease, underscoring the deterministic malignant potential of hereditary EV. This study broadens the genetic and phenotypic spectrum of TMC6/TMC8 -associated EV, establishes complex structural rearrangement in the molecular etiology, and consolidates hereditary EV as a recessive cancer predisposition syndrome. Integrating high-resolution genome mapping into diagnostic workflows may uncover concealed allelic architecture in unresolved hereditary cancer syndromes.
- 18 February 2026
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (3) , 429-437
Open AccessTMC6/8-associated epidermodysplasia verruciformis: germline variants and a complex structural alteration in a skin cancer predisposition syndrome
Hereditary epidermodysplasia verruciformis (EV) represents a paradigmatic inherited cutaneous syndrome linking viral susceptibility, immunity, and oncogenesis. Although biallelic variants in CIB1 , TMC6 , and TMC8 —encoding components of the keratinocyte-intrinsic antiviral complex—underlie most cases, the full mutational spectrum and its oncologic implications remain incompletely defined. We performed integrated genomic, histopathological, and longitudinal clinical analyses in six affected individuals from five unrelated families with confirmed hereditary EV. Comprehensive short-read sequencing, copy-number assessment, and optical genome mapping (OGM) were used to delineate the underlying genetic alterations, followed by long-range PCR and Sanger validation. Pathogenic or likely pathogenic germline variants affecting TMC6 or TMC8 were identified in all probands, providing molecular confirmation of disease. Four variants were novel, including splice-site, frameshift, and in-frame deletions. In one proband, OGM revealed a previously unrecognised complex del–inv–del structural variant spanning both TMC6 and TMC8 —the first reported example in hereditary EV. This rearrangement, confirmed at base-pair resolution, co-segregated with a synonymous TMC8 variant that served as a practical haplotypic marker for carrier testing. Clinically, all patients developed cutaneous squamous cell carcinoma (SCC), and several exhibited multifocal or aggressive disease, underscoring the deterministic malignant potential of hereditary EV. This study broadens the genetic and phenotypic spectrum of TMC6/TMC8 -associated EV, establishes complex structural rearrangement in the molecular etiology, and consolidates hereditary EV as a recessive cancer predisposition syndrome. Integrating high-resolution genome mapping into diagnostic workflows may uncover concealed allelic architecture in unresolved hereditary cancer syndromes.
- 30 September 2025
- Published by Ministry of Health, Ankara City Hospital in Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi
- Vol. 22 (3) , 380-386
A Cross-Sectional Study of CHEK2 Pathogenic Variants: Cancer Risk Spectrum and Clinical Insights
Aims: CHEK2 is a tumor suppressor gene involved in DNA damage response and a moderate-risk gene for breast cancer. However, its role in other malignancies remains unclear, and the clinical impact of biallelic CHEK2 mutations is not well understood. This study aims to expand the cancer risk spectrum of CHEK2, including rare tumors, and to provide insights into the phenotypes associated with biallelic mutations and Multiple Inherited Neoplasia Alleles Syndrome (MINAS). Materials and Methods: We analyzed 40 individuals from 34 families carrying CHEK2 mutations, identified via multigene panel testing for hereditary cancer syndromes. Next-generation sequencing was performed for the probands, and segregation analysis in affected relatives was conducted using Sanger sequencing. Clinical data, including cancer type, age at diagnosis, and family history, were obtained from medical records and clinical evaluations. Results: We identified 16 distinct CHEK2 mutations, with c.1427C>T (p.Thr476Met) being the most frequent. Breast cancer was the most common diagnosis (75%), followed by thyroid cancer and rare tumors, including pancreatic neuroendocrine and cerebellopontine angle tumors. Multiple primary cancers occurred in 15% of patients, and 10% had MINAS, harboring additional variants in genes like PTEN and BRCA2. Biallelic CHEK2 mutations were linked to severe phenotypes, including bilateral breast cancer and adolescent-onset polyposis. Conclusions: Our findings broaden the CHEK2-associated cancer spectrum, extending beyond breast cancer to include rare malignancies and complex presentations. The identification of biallelic mutations and MINAS underscores the need for comprehensive genetic testing and tailored surveillance. These insights are crucial for refining risk assessment, enhancing prevention, and improving clinical management for individuals harboring CHEK2 mutations.
- 30 September 2025
- Published by Ministry of Health, Ankara City Hospital in Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi
- Vol. 22 (3) , 380-386
A Cross-Sectional Study of CHEK2 Pathogenic Variants: Cancer Risk Spectrum and Clinical Insights
Aims: CHEK2 is a tumor suppressor gene involved in DNA damage response and a moderate-risk gene for breast cancer. However, its role in other malignancies remains unclear, and the clinical impact of biallelic CHEK2 mutations is not well understood. This study aims to expand the cancer risk spectrum of CHEK2, including rare tumors, and to provide insights into the phenotypes associated with biallelic mutations and Multiple Inherited Neoplasia Alleles Syndrome (MINAS). Materials and Methods: We analyzed 40 individuals from 34 families carrying CHEK2 mutations, identified via multigene panel testing for hereditary cancer syndromes. Next-generation sequencing was performed for the probands, and segregation analysis in affected relatives was conducted using Sanger sequencing. Clinical data, including cancer type, age at diagnosis, and family history, were obtained from medical records and clinical evaluations. Results: We identified 16 distinct CHEK2 mutations, with c.1427C>T (p.Thr476Met) being the most frequent. Breast cancer was the most common diagnosis (75%), followed by thyroid cancer and rare tumors, including pancreatic neuroendocrine and cerebellopontine angle tumors. Multiple primary cancers occurred in 15% of patients, and 10% had MINAS, harboring additional variants in genes like PTEN and BRCA2. Biallelic CHEK2 mutations were linked to severe phenotypes, including bilateral breast cancer and adolescent-onset polyposis. Conclusions: Our findings broaden the CHEK2-associated cancer spectrum, extending beyond breast cancer to include rare malignancies and complex presentations. The identification of biallelic mutations and MINAS underscores the need for comprehensive genetic testing and tailored surveillance. These insights are crucial for refining risk assessment, enhancing prevention, and improving clinical management for individuals harboring CHEK2 mutations.